ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
INVESTORS
[서울경제] 큐로셀 “국산 1호 CAR-T 치료제 내년 출시…2주내 투약 가능”
2024/12/23
큐로셀 ‘국산 1호 CAR-T 치료제 내년 출시…2주내 투약 가능’ | 서울경제
Prev
[더벨] 국산 CAR-T 현실화에 이제는 글로벌, 차별화는 ‘언멧니즈’
Next
[팜뉴스] 국내 첫 CAR-T 치료제 안발셀, “중증 혈액암 환자들에게 더 빠른 치료 기회 제공할 것”
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.
